UTHR

United Therapeutics Corporation (UTHR)

Last Price$365.0(0.4%)
Market Cap$16.2B
LTM Net Debt
($2,926.5M)
YoY Growth
-29.2%
3Y CAGR
+34.6%
5Y CAGR
+38.8%
Stock quality & Intrinsic value
8/10
15.5% undervalued

United Therapeutics Corporation Net Debt

Annual
Quarterly
LTM
Crunching data... Almost there!
Dec'04Dec'05Dec'06Dec'07Dec'08Dec'09Dec'10Dec'11Dec'12Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
Net Debt
($82.8M)
($125.5M)
$22.3M
($40.0M)
$43.2M
$21.1M
($322.2M)
($209.3M)
($204.2M)
($402.4M)
($569.1M)
($948.4M)
($1,050.8M)
($1,180.1M)
($1,608.5M)
($1,403.4M)
($2,184.6M)
($2,780.6M)
($3,354.9M)
($2,294.1M)
UTHR
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for UTHR and see if it's the right time to invest.
Dive in

United Therapeutics Corporation (UTHR) Net Debt comparison analysis

Crunching data... Almost there!

UTHR key stats

USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Crunching data... Almost there!

Discover more Stock Ideas

Loved by
investors
worldwide
10K+
Investors use our platform
#1
Top value investing hub with all necessary tools
1K+
Experienced investors in our community
4.9
Average rating across all rating platforms

FAQ

1) What is United Therapeutics Corporation's Net Debt?

As of today, United Therapeutics Corporation's last 12-month Net Debt is ($2,926.5M), based on the financial report for Sep 30, 2024 (Q3 2024).

2) What is United Therapeutics Corporation's Net Debt growth rate?

Over the last year, United Therapeutics Corporation's Net Debt growth was (29.2%). The average annual Net Debt growth rates for United Therapeutics Corporation have been 46.5% over the past three years, 38.8% over the past five years.

3) Is United Therapeutics Corporation's Net Debt growth rate Good?

Over the last year, United Therapeutics Corporation's Net Debt growth was (29.2%), which is lower than industry growth of (0.1%). It indicates that United Therapeutics Corporation's Net Debt growth is Good.

4) How does United Therapeutics Corporation's Net Debt growth rate compare to its peers?

Over the last year, United Therapeutics Corporation's Net Debt growth was (29.2%), which is higher than peer median growth of (45.7%). The list of peers includes MRNA, ALNY, BGNE, INCY, GMAB, NVO, VRTX, REGN, BNTX, ARGX etc.